Tuesday, February 22, 2011, 8:07 AM
Forest Laboratories (FRX) to acquire Clinical Data (CLDA) for $30/share in cash and another $6/share on milestones. The $1.2B deal is a 6.6% premium to the average share price since CLDA announced FDA approval of its major depressive disorder treatment Viibryd, which sent shares up more than 50%. (PR)
Comment!
Monday, January 24, 2011, 1:52 PMEight underperforming stocks with increasing put/call ratios, according to Kapitall: Clinical Data (CLDA), Home Inns & Hotels (HIHM), Supervalu (SVU), Volcom (VLCM), Orbitz (OWW), Ctrip.com (CTRP), Clearwire (CLWR), Taseko Mines (TGB). Contrarians may believe these stocks are set to rally based on a high number of open put positions relative to call positions.
Comment!
Monday, January 24, 2011, 9:24 AM
Clinical Data (CLDA) announces that its major depressive disorder treatment Viibryd received approval from the FDA. The biotech company says the drug should be available in U.S. pharmacies in Q2. CLDA +67.3% premarket. (PR)
Comment!
Asif Suria Forest Laboratories Completes Acquisition of Clinical Data, Inc. $CLDA $FRX
4/14/11
Reply
•!Report Abuse
View all 0 replies
Wall Street Teacher Well, I guess we will soon see if the speculation concerning a CLDA funds move to ZIOP is correct. Deal is scheduled to close early April.
3/31/11
Reply
•!Report Abuse
View all 0 replies
TheMarketFinancial On Sunday we will release our $16 PPS valuation model for $OPTR, #biotech #optimer $SPY $SPX $CLDA $GSK #buyout #takeover #cdi
3/25/11
Reply
•!Report Abuse
View all 0 replies
TheMarketFinancial $19 a share buyout rumours for $OPTR Optimer Pharmaceuticals...analysts finally tuning in on the next $CLDA?